11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$69M | — | — | -$51M | — | $77M |
| 2024 | — | -$35M | — | — | -$31M | — | $22M |
| 2023 | — | -$31M | — | — | -$29M | — | $37M |
| 2022 | — | -$14M | — | — | — | — | $41M |
| 2021 | — | -$22M | — | — | — | — | $42M |
| 2020 | — | -$46M | — | — | — | — | $59M |
| 2019 | $36000 | -$4M | 0.0% | -11288.9% | -$3M | — | $7M |
| 2018 | $18M | -$49M | 0.0% | -254.2% | -$36M | $26M | $41M |
| 2017 | $41000 | -$39M | 0.0% | -91775.6% | -$32M | $4M | $36M |
| 2016 | $49000 | -$33M | 0.0% | -64673.5% | -$30M | $10M | $6M |
| 2015 | — | -$23M | — | — | — | — | $8M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$22M | — | — | -$19M | — | $58M |
| Dec '25 | — | -$25M | — | — | -$16M | — | $77M |
| Sep '25 | — | -$18M | — | — | -$14M | — | $93M |
| Jun '25 | — | -$11M | — | — | -$10M | — | $106M |
| Mar '25 | — | -$16M | — | — | -$10M | — | $46M |
| Dec '24 | — | -$7M | — | — | -$10M | — | $22M |
| Sep '24 | — | -$8M | — | — | -$8M | — | $16M |
| Jun '24 | — | -$13M | — | — | -$6M | — | $24M |
| Mar '24 | — | -$7M | — | — | -$7M | — | $30M |
| Dec '23 | — | -$6M | — | — | -$9M | — | $37M |
| Sep '23 | — | -$10M | — | — | — | — | $46M |
| Jun '23 | — | -$9M | — | — | — | — | $20M |
| Mar '23 | — | -$7M | — | — | — | — | $36M |
| Dec '22 | — | -$5M | — | — | — | — | $41M |
| Sep '22 | — | -$3M | — | — | — | — | $44M |
| Jun '22 | — | -$3M | — | — | — | — | $39M |
| Mar '22 | — | -$3M | — | — | — | — | $40M |
| Dec '21 | — | -$3M | — | — | — | — | $42M |
| Sep '21 | — | -$8M | — | — | — | — | $46M |
| Jun '21 | — | -$6M | — | — | — | — | $51M |
Over the past 5 years, Forte Biosciences, Inc.'s revenue has declined 9.8% per year. These are computed facts, not advice.
As of FY2025, Forte Biosciences, Inc. reported — of total debt against $77M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.